Alastair D. Reith

GlaxoSmithKline Pharmaceuticals R&D
Stevenage, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Addressing the Challenges of Translating LRRK2 Biology into Disease-Modifying Therapies: The LRRK2 Investigative Therapeutics Exchange Initiative.

Addressing the Challenges of Translating LRRK2 Biology into Disease-Modifying Therapies: The LRRK2 Investigative Therapeutics Exchange Initiative.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: April 16, 2026

Repurposed drug prioritization pipeline for a multi-arm platform trial in clinical Alzheimer's disease.

Repurposed drug prioritization pipeline for a multi-arm platform trial in clinical Alzheimer's disease.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: January 29, 2026

Discovery and optimization of pyrrolopyrimidines as highly potent, selective and brain-penetrant LRRK2 inhibitors.

Discovery and optimization of pyrrolopyrimidines as highly potent, selective and brain-penetrant LRRK2 inhibitors.

Journal: RSC medicinal chemistry

Published: September 24, 2025

A community-led initiative to de-risk and advance Parkinson's disease therapeutic targets.

A community-led initiative to de-risk and advance Parkinson's disease therapeutic targets.

Journal: NPJ Parkinson's disease

Published: April 03, 2025

Tau uptake by human neurons depends on receptor LRP1 and kinase LRRK2.

Tau uptake by human neurons depends on receptor LRP1 and kinase LRRK2.

Journal: The EMBO journal

Published: January 27, 2025

Impact of Type II LRRK2 inhibitors on signaling and mitophagy.

Impact of Type II LRRK2 inhibitors on signaling and mitophagy.

Journal: The Biochemical journal

Published: May 24, 2021

Pharmacological rescue of impaired mitophagy in Parkinson's disease-related LRRK2 G2019S knock-in mice.

Pharmacological rescue of impaired mitophagy in Parkinson's disease-related LRRK2 G2019S knock-in mice.

Journal: eLife

Published: February 17, 2021

5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacy.

5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacy.

Journal: Bioorganic & medicinal chemistry letters

Published: September 13, 2018

Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors.

Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: January 02, 2018

LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages.

LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages.

Journal: The EMBO journal

Published: November 21, 2017

Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors.

Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: June 01, 2017

Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors.

Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors.

Journal: The Biochemical journal

Published: June 08, 2016

Showing 1-12 of 17

Last Updated: 09/26/2026